Zobrazeno 1 - 10
of 132
pro vyhledávání: '"David A. Sclar"'
Publikováno v:
BMC Geriatrics, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Injurious falls among older adults are both common and costly. The prevalence of falls is known to increase with age and with use of fall-risk drugs/potentially inappropriate medications (FRD/PIM). Little is known about the joint
Externí odkaz:
https://doaj.org/article/0888bfd05b7c4c9cbcf5048b85dd606e
Publikováno v:
BMC Research Notes, Vol 11, Iss 1, Pp 1-8 (2018)
Abstract Objective To conduct a proof-of-concept study comparing Lorenz-curve analysis (LCA) with power-law (exponential function) analysis (PLA), by applying segmented regression modeling to 1-year prescription claims data for three medications—al
Externí odkaz:
https://doaj.org/article/019a728f76de492392a28f759a741819
Publikováno v:
Drug, Healthcare and Patient Safety, Vol Volume 10, Pp 37-43 (2018)
Drug, Healthcare and Patient Safety
Drug, Healthcare and Patient Safety
Kyle C Molina, Kathleen A Fairman, David A Sclar Department of Pharmacy Practice, Midwestern University College of Pharmacy–Glendale, Glendale, AZ, USA Background: Opioids are not recommended for routine treatment of migraine because their benefits
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4acd21ca455ac72dbf9b83fd1ceae961
https://www.dovepress.com/concomitant-use-of-opioid-medications-with-triptans-or-serotonergic-an-peer-reviewed-article-DHPS
https://www.dovepress.com/concomitant-use-of-opioid-medications-with-triptans-or-serotonergic-an-peer-reviewed-article-DHPS
Publikováno v:
Drug Safety. 41:213-228
Overuse of gabapentin and/or opioids occurs in a small percentage of patients at > 3-fold labeled dosages. Gabapentin may potentiate opioid effects. The aim was to assess patient harm, defined as use of inpatient hospital (IPH) or emergency departmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72822330a4f9283328b4765d415c2c1d
https://doi.org/10.1007/s40264-017-0595-1
https://doi.org/10.1007/s40264-017-0595-1
Publikováno v:
Publons
Therapeutics and Clinical Risk Management
Therapeutics and Clinical Risk Management
Kathleen A Fairman, Lindsay E Davis, David A Sclar Department of Pharmacy Practice, College of Pharmacy, Midwestern University-Glendale, Glendale, AZ, USA Background: Inconsistency of real-world medication use with labeled indications may affect cost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::735656654acd163f3eb9404ac51f9e19
https://doi.org/10.2147/tcrm.s143008
https://doi.org/10.2147/tcrm.s143008
Publikováno v:
Journal of Attention Disorders. 24:10-19
Objective: The aim of this article is to update ADHD diagnosis/treatment trends by age, gender, and race. Method: National Ambulatory Medical Care Survey data were obtained for 2008-2009 to 2012-2013. Physician office visits including ADHD diagnosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84c33840afb170565de4c87f912f6f1
https://doi.org/10.1177/1087054716688534
https://doi.org/10.1177/1087054716688534
Autor:
Alyssa M. Peckham, David A. Sclar
Publikováno v:
The primary care companion for CNS disorders. 21(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::638eb7a1c40d2c981bb8bbf11fd283ed
https://pubmed.ncbi.nlm.nih.gov/30085436
https://pubmed.ncbi.nlm.nih.gov/30085436
Publikováno v:
Diabetes Spectrum : A Publication of the American Diabetes Association
Obesity, defined as a BMI ≥30 kg/m2, is one of the most common and costly preventable causes of death in the United States (1–3). Increased prevalence of obesity, which affects an estimated 36.5% of U.S. adults (1), has been linked to a growing r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2335462ffef61e121b7a1969ed677df2
https://pubmed.ncbi.nlm.nih.gov/30853765
https://pubmed.ncbi.nlm.nih.gov/30853765
Autor:
Alyssa M. Peckham, David A. Sclar
Publikováno v:
BMJ (Clinical research ed.). 363
Mayor notes that the United Kingdom will reclassify pregabalin and gabapentin—that is, gabapentinoids—as class C controlled substances in April 2019. This change was proposed, in part, owing to the increased rate of death associated with gabapent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f77444a40c7ae0043f5eb1689fc56a6
https://pubmed.ncbi.nlm.nih.gov/30327316
https://pubmed.ncbi.nlm.nih.gov/30327316
Publikováno v:
Applied Health Economics and Health Policy. 15:203-214
Faced with rising healthcare costs, state Medicaid programs need short-term, easily calculated budgetary estimates for new drugs, accounting for medical cost offsets due to clinical advantages. To estimate the budgetary impact of direct-acting oral a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d582dc6690dbb017aee632741fe3a38
https://doi.org/10.1007/s40258-016-0295-5
https://doi.org/10.1007/s40258-016-0295-5